Landmark Glaucoma Studies
-
Upload
jasper-roy -
Category
Documents
-
view
63 -
download
0
description
Transcript of Landmark Glaucoma Studies
![Page 1: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/1.jpg)
LANDMARK GLAUCOMA STUDIES
TARIQ ALASBALI
WHICH PATIENTS ARE AT RISK FOR THE PROGRESSION?
![Page 2: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/2.jpg)
``Doctor is my glaucoma likely to get worse?``
![Page 3: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/3.jpg)
``Doctor will my eye condition get worse?``
What is the diagnosis (OHT vs NTG vs POAG early or late ?)
Does the patient have the published risk Factor for progression?
![Page 4: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/4.jpg)
Risk of Progression
Diagnosis Risk of progression with no Rx (%)
Risk of progression with Rx (%)
OHTOHT study 5 yrs
NTG(CNTG study 6 yrs )
Early POAG(EMGS study 6 yrs )
Advanced POAG(AGIS-7 yrs)
![Page 5: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/5.jpg)
Ocular hypertension treatment study
Aim To determine if glaucoma drops delays
or prevents glaucoma in ocular hypertensives
Arch Ophthalmol 120: 701-713, 2002.
![Page 6: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/6.jpg)
OHTS - methods
RCT of 1600 patients IOP 24-32mmHg in one eye and 21-
32 in other eye Normal discs and fields
Drops prescribed to achieve IOP of ≤24mmHg AND at least 20% drop from baseline
![Page 7: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/7.jpg)
Results
At 5 years 4.4% of treated group had progressed to
POAG 9.5% of untreated
![Page 8: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/8.jpg)
Risk of Progression
Diagnosis Risk of progression with no Rx (%)
Risk of progression with Rx (%)
OHTOHT study 5 yrs
9.5 4.4
NTG(CNTG study 6 yrs )
Early POAG(EMGS study 6 yrs )
Advanced POAG(AGIS-7 yrs)
![Page 9: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/9.jpg)
![Page 10: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/10.jpg)
What are the risk factors for
progression with OHT?
OHTS study
![Page 11: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/11.jpg)
OHTS conclusions
Factors associated with progression ``I treat if:``
Older age High CDR (vertical or horizontal) > 0.4 High PSD IOP Thinner cornea
![Page 12: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/12.jpg)
CCT and Glaucoma Risk
![Page 13: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/13.jpg)
What are the risk factors for
progression in NTG?
NTGS study
![Page 14: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/14.jpg)
Risk of Progression
Diagnosis Risk of progression with no Rx (%)
Risk of progression with Rx (%)
OHTOHT study 5 yrs
NTG(CNTG study 6 yrs )
Early POAG(EMGS study 6 yrs )
Advanced POAG(AGIS-7 yrs)
![Page 15: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/15.jpg)
Normal tension glaucoma study
Aim To determine if IOP plays a part in NTG
![Page 16: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/16.jpg)
NTGS - methods
239 patients recruited
Uni or bilateral NTG as defined by IOP <21 in 10 baseline measurements
AND Glaucomatous cupping Defined type and severity of field loss
![Page 17: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/17.jpg)
NTGS - methods
Randomised immediately if VF defect threatening fixation Previously documented disease
progression
Others randomised when evidence of progression
![Page 18: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/18.jpg)
NTGS
145 (of 239) patients randomised One eye randomised to
Treatment Drops, ALT or surgery to achieve 30%
reduction in IOP No treatment until evidence of
progression Other eye could be treated in this group
![Page 19: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/19.jpg)
NTGS results
30% drop achieved in half without surgery
Once 30% drop achieved rate of progressive field loss was lower than group that did not receive treatment (after allowing for cataract effect which was higher in treated group)
![Page 20: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/20.jpg)
NTGS results
Rate of progression in untreated NTG highly variable
Half did not progress on VF in 5 years Factors associated with progression
Female Migraine Disc haemorrhages on presentation
![Page 21: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/21.jpg)
NTGS conclusions
Overall, lowering IOP in NTG slows progression.
However, over half of patients did not progress without treatment at 5 years.
![Page 22: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/22.jpg)
Risk of Progression
Diagnosis Risk of progression with no Rx (%)
Risk of progression with Rx (%)
OHTOHT study 5 yrs
NTG(CNTG study 6 yrs )
60 20
Early POAG(EMGS study 6 yrs )
Advanced POAG(AGIS-7 yrs)
![Page 23: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/23.jpg)
What are the risk factors for
progression in NTG?
NTGS study
![Page 24: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/24.jpg)
• Factors associated with progression• ``I am aggressive if:``–Female–Migraine–Disc haemorrhages on presentation
![Page 25: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/25.jpg)
What are the risk factors for
progression in early glaucoma?
EMGS study
![Page 26: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/26.jpg)
Risk of Progression
Diagnosis Risk of progression with no Rx (%)
Risk of progression with Rx (%)
OHTOHT study 5 yrs
NTG(CNTG study 6 yrs )
Early POAG(EMGS study 6 yrs )
Advanced POAG(AGIS-7 yrs)
![Page 27: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/27.jpg)
Early Manifest Glaucoma Trial•Compared immediate treatment
versus no (or delayed) treatment for patients with newly diagnosed POAG
•Diagnosis based on reproducible visual field defects
• Included NTG
![Page 28: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/28.jpg)
EMGT
•255 patients•Randomised to ▫ ALT and betaxolol▫No treatment
• If IOP >25mmHg in treated (>35 untreated)→ Latanoprost added
• If remains high → individualised treatment
![Page 29: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/29.jpg)
EMGT
End point Progression of field and/or disc
![Page 30: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/30.jpg)
EMGT - results
Over 6 years 62% untreated versus 45% of treated
group progressed Median time to progression 66 months
treated versus 48 months untreated
![Page 31: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/31.jpg)
Risk of Progression
Diagnosis Risk of progression with no Rx (%)
Risk of progression with Rx (%)
OHTOHT study 5 yrs
NTG(CNTG study 6 yrs )
Early POAG(EMGS study 6 yrs )
62 45
Advanced POAG(AGIS-7 yrs)
![Page 32: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/32.jpg)
What are the risk factors for
progression in early glaucoma?
EMGS study
![Page 33: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/33.jpg)
Early POAG risk factors (EMGS)
Baseline factors Pseudoexfoliation Older age Higher IOP Worse mean
deviation
Follow up factors IOP
Each 1mmHg reduction from baseline reduced risk of progression by 10%
Disc haemorrhages
![Page 34: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/34.jpg)
Early POAG risk factors (EMGS)
• Factors associated with progression• ``I am aggressive if:`` Pseudo exfoliation
Bilateral disease Older age Higher IOP Worse mean
deviation Disc hemorrhage
![Page 35: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/35.jpg)
Risk of Progression-Advanced glaucoma
Diagnosis Risk of progression with no Rx (%)
Risk of progression with Rx (%)
OHTOHT study 5 yrs
NTG(CNTG study 6 yrs )
Early POAG(EMGS study 6 yrs )
Advanced POAG(AGIS-7 yrs)
![Page 36: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/36.jpg)
Advanced Glaucoma Intervention Study
Aim To assess the outcome of sequences of
laser and surgical interventions in eyes that have failed on medical treatment
![Page 37: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/37.jpg)
AGIS
•POAG, uncontrolled with drops•Randomised to 2 groups
1. Trab → ALT → Trab2. ALT → Trab → ALT
Medical treatment as required789 patients followed up for at least 5
years
![Page 38: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/38.jpg)
AGIS outcomes
Primary outcome Decreased vision (substantial VA or VF
decrease)
![Page 39: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/39.jpg)
AGIS results
Vision better in blacks if had ALT first In whites
Vision better in laser group for first 4 years
Then better in surgery group
![Page 40: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/40.jpg)
AGIS results
Side arm looked at IOP and VF loss
Divided into 2 groups IOP <18mmHg at 100% visits (mean =
12.3mmHg) = little VF deterioration IOP <18mmHg at <50% of study visits
(mean = 20.2mmHg) = significantly more VF deterioration
![Page 41: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/41.jpg)
100% of visits < 18mmHg
50-75% of visits < 18mmHg
0% of visits < 18mmHg
75-100% of visits < 18mmHg
![Page 42: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/42.jpg)
AGIS conclusions (1992)
Blacks should have laser first Whites should have trab first
![Page 43: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/43.jpg)
AGIS conclusions
Relationship between low IOP and VF loss remains important finding
In advanced glaucoma, lowering IOP to low teens means most will not progress
![Page 44: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/44.jpg)
Risk of Progression-Advanced glaucoma
Diagnosis Risk of progression with no Rx (%)
Risk of progression with Rx (%)
OHTOHT study 5 yrs
NTG(CNTG study 6 yrs )
Early POAG(EMGS study 6 yrs )
Advanced POAG(AGIS-7 yrs)
Not Known 30 VA 14 VF(IOP <15mmhg)
![Page 45: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/45.jpg)
Factors associated with progression ``I am aggressive if:``
Older age Lower education Good VA DM High IOP > 18 IOP fluctuation
AGIS conclusions
![Page 46: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/46.jpg)
Collaborative Initial Glaucoma Treatment Study (CIGTS)
Does not provide direct evidence that IOP has an impact on glaucomatous progression, but you need to know about it…
AIM:to assess the effect on early-diagnosed OAG of initial Tx with either topical meds or trab
![Page 47: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/47.jpg)
CIGTS - Methods
Prospective RCT OAG (POAG, Pigmentary, PEX) N=607 Randomized → Medical management
↘ Trabeculectomy IOP target customized for each
patient Primary End Point: progression of VF
loss
![Page 48: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/48.jpg)
CIGTS – Results at 5yrs
Medical Treatment
Surgical Treatment
IOP reduction 28mmHg→17-18mmHg
27mmHg→14-15mmHg
Progression at 5 years
No progression No progression
• Surgical group is at increased risk of visual loss initially but by 4yrs both groups are comparable
![Page 49: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/49.jpg)
CIGTS summary
Surgery resulted in Lower IOP More cataract More ocular side effects Initial ↓ vision Initial ↓ visual field
![Page 50: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/50.jpg)
CIGTS conclusions
Results do not support altering current practice of medical treatment first
![Page 51: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/51.jpg)
``Doctor is my glaucoma likely to get worse?``
![Page 52: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/52.jpg)
Diagnosis Risk of progression with no Rx (%)
Risk of progression with Rx (%)
OHTOHT study 5 yrs
9.5 4.4
NTG(CNTG study 6 yrs )
60 20
Early POAG(EMGS study 6 yrs )
62 45
Advanced POAG(AGIS-7 yrs)
Not Known 30 VA14 VF(IOP <15mmhg)
RISK OF PROGRESSIONTHE BEST EVIDENCE SUMMARY
![Page 53: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/53.jpg)
Risk Factors for Progression
Factors OH Glaucoma Glaucoma ProgressionHigher age OHTS AGIS, CIGTS, EMGT
CCT OHTS
C:D ratio OHTS
Diabetes mellitus OHTS AGIS, CIGTS
Disc hemorrhage EMGT , NTGS
IOP (higher) OHTS EMGT
IOP (over f/u) OHTS EMGT
Male OHTS AGIS
PXF EMGT
Race (non-white) OHTS CIGTS
Visual field OHTS EMGT
![Page 54: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/54.jpg)
Glaucoma Risk Calculation Results
Patient Age - - - 65Corneal Thickness - - - 490 micronsIOP - - - 23PSD - - - 1.4Vertical Cup / Disk Ratio - - - 0.7
Risk of developing glaucoma within the next five years.Risk without treatment - - - 41.71 %Risk with treatment - - - 16.68 %
![Page 55: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/55.jpg)
Patient Age - - - 65Corneal Thickness - - - 550 micronsIOP - - - 23PSD - - - 1.4Vertical Cup / Disk Ratio - - - 0.7
Glaucoma Risk Calculation Results
Risk of developing glaucoma within the next five years.Risk without treatment - - - 16.86%Risk with treatment - - - 6.74 %
![Page 56: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/56.jpg)
My “take home messages”
1. Every mmHg helps (EMGT)2. If get IOP very low (12mmHg) most
patients will not progress (AGIS)3. NTG is a funny disease
- Many do not progress- If do – only proven treatment is reducing IOP
4. Not all OHT needs treated – assess risk on individual basis and discuss with patient
![Page 57: Landmark Glaucoma Studies](https://reader033.fdocuments.us/reader033/viewer/2022061503/56812d89550346895d929f00/html5/thumbnails/57.jpg)